



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Complete if Known

Application Number	09/691,889
Filing Date	October 20, 2000
First Named Inventor	FELD Yair et al
Art Unit	1632
Examiner Name	Falk
Attorney Docket Number	00/20989

Sheet	1	of	3
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Country Code ² Number ⁴ Kind Code ³ (if known)				
Amz	6	WO02/087419	11-07-2002	Marban et al		
Amz	7	WO00/63434	10-26-2000	Abbott et al		
Examiner Signature	Anne-Marie Falk			Date Considered	4/12/05	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/691,889		
			Filing Date	October 20, 2000		
			First Named Inventor	FELD Yair et al		
			Group Art Unit			
			Examiner Name			
Sheet	2	Of	3	Attorney Docket Number	00/20989	
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²	
Amz	8	Feld et al. "Electrophysiological Modulation of Cardiomyocytic Tissue by Transfected Fibroblasts Expressing Potassium Channels: A Novel Strategy to Manipulate Excitability", Circulation 105(4): 522-9, 2002.				
	9	Hammond et al. "Angiogenic Gene Therapy for Heart Disease: A Review of Animal Studies and Clinical Trials", Cardiovasc Res 49(3): 561-7, 2001.				
	10	DeGroot et al. "Clinical Review 131: Gene Therapy for Thyroid Cancer: Where Do We Stand?", J Clin Endocrinol Metab 86(7): 2923-8, 2001.				
	11	Siegel "Biotechnology and Clinical Trials", J Infect Dis 185(Suppl 1): S52-7, 2002.				
	12	Reinlib et al. "Cell Transplantation as Future Therapy for Cardiovascular Disease?: A Workshop of the National Heart, Lung, and Blood Institute", Circulation 101(18): E182-7, 2000.				
	13	Roth et al. "Nonviral Transfer of the Gene Encoding Coagulation Factor VIII in Patients With Severe Hemophilia A", N Engl J Med 344(23): 1735-42, 2001.				
	14	Fast et al, "Anisotropic conduction in monolayers of neonatal rat heart cells cultured on collagen substrate", Circ Res. 1994 Sep;75(3):591-5.				
	15	Marshall "Gene Therapy's Growing Pains", Science 269: 1050-1055, 1995.				
	16	Verma et al. "Gene Therapy - Promises, Problems and Prospects", Nature 389(6648): 239-42, 1997.				
	17	Johns et al, "Adenovirus-mediated expression of a voltage-gated potassium channel in vitro (rat cardiac myocytes) and in vivo (rat liver). A novel strategy for modifying excitability.", J Clin Invest. 1995 Aug;96(2):1152-8.				
	18	Nuss et al, "Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes", J Clin Invest. 1999 Mar;103(6):889-96.				
	19	Donahue et al, "Focal modification of electrical conduction in the heart by viral gene transfer", Nat Med. 2000 Dec;6(12):1395-8.				
	20	Miller et al. "Targeted Vectors for Gene Therapy", FASEB J. 9(2): 190-9, 1995.				
	21	Orkin et al. "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy": 1-40 1995, + http://nih.gov/news/panelrep.html (1975).				
	22	Koh et al. "Differentiation and Long-Term Survival of C2C12 Myoblast Grafts in Heart", J Clin Invest 92(3): 1548-54, 1993.				
	23	Soonpaa et al. "Formation of Nascent Intercalated Disks Between Grafted Fetal Cardiomyocytes and Host Myocardium", Science 264(5155): 98-101, 1994.				
	Signature		Anne-Marie Falk		Considered	4/12/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/691,889
				Filing Date	October 20, 2000
				First Named Inventor	FELD Yair et al
				Group Art Unit	
				Examiner Name	
Sheet	3	Of	3	Attorney Docket Number	00/20989
Am2	22	Rook et al, "Differences in gap junction channels between cardiac myocytes, fibroblasts, and heterologous pairs", Am J Physiol. 1992 Nov;263(5 Pt 1):C959-77.			
	23	Gussoni et al. "Normal Dystrophin Transcripts Detected in Duchenne Muscular Dystrophy Patients After Myoblast Transplantation", Nature 356(6368): 435-8, 1992.			
	24	Freed et al. "Survival of Implanted Fetal Dopamine Cells and Neurologic Improvement 12 to 46 Months After Transplantation for Parkinson's Disease", N Engl J Med 327(22): 1549-55, 1992.			
	25	Jockusch et al. "Long-Term Expression of Isomyosins and Myoendocrine Functions in Ectopic Grafts of Atrial Tissue", Proc Natl Acad Sci USA 83(19): 7325-9, 1986.			
	26	Bader et al. "Repair and Reorganization of Minced Cardiac Muscle in the Adult Newt (Notophthalmus Viridescens)", J Morphol 155(3): 349-57, 1978.			
	27	Lerche et al. "Ion Channels and Epilepsy", Am J Med Genet 106(2): 146-59, 2001.			
	28	Luo et al. "A Model of the Ventricular Cardiac Action Potential. Depolarization, Repolarization, and Their Interaction", Circ Res 68(6): 1501-26, 1991.			
	29	Marom et al. "Modeling State-Dependent Inactivation of Membrane Currents", Biophys J. 67(2): 515-20, 1994.			
	30	Marom "Slow Changes in the Availability of Voltage-Gated Ion Channels: Effects on the Dynamics of Excitable Membranes", J Membr Biol 161(2): 105-13, 1998.			
Am2	31	Marom et al. "State-Dependent Inactivation of the Kv3 Potassium Channel", Biophysical Journal 67: 579-589, 1994.			

Signature	Anne-Marie Zalk	Considered	4/12/05
-----------	-----------------	------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/691,889
--------------------	------------

Filing Date	October 20, 2000
-------------	------------------

First Named Inventor	FELD Yair et al
----------------------	-----------------

Group Art Unit	1632
----------------	------

Examiner Name

Sheet	1	Of	1	Attorney Docket Number	00/20989
-------	---	----	---	------------------------	----------

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
----------------------	--------------------------	---	----------------

Am7	1	Crystal "Transfer of Genese to Humans: Early Lessons and Obstacles to Success", Science 270: 404-410, 1995.
-----	---	--

2	Deonarain "Ligand-Targeted Receptor-Mediated Vectors for Gene Delivery", Exp. Opin. Ther. Patents 8(1): 53-69, 1988.
---	--

	3	Friedmann "Overcoming the Obstacles to Gene Therapy", Sci Am 276(6): 96-101, 1997.
--	---	--

	4	Jackowski "Neural Injury Repair: Hope for the Future as Barriers to Effective CNS Regeneration Become Clearer", British Journal of Neurosurgery 9(3): 303-17, 1995.
--	---	---

	5	Sangro et al. "Gene Therapy of Neoplastic Liver Diseases", International Journal of Cell Biology. 35(2): 135-148, 2003. Abstract.
--	---	---

	6	Bruckner "INGN-201. Introgen Therapeutics", Current Opinion Invetigating Drugs, 2(12): 1776-1785. 2001. Abstract.
--	---	---

7	Nasz et al. "Recombinant Adenovirus Vectors for Gene Therapy and Clinical Trials", <i>Acta Microbiol. Immunol. Hung.</i> 48(3-4): 323-348, 2001. Abstract.
---	--

	8	Cohen et al. "ONYX-015-Onyx Pharmaceuticals", Current Opinion Investigating Drugs. 2(12): 1770-1775. 2001. Abstract.
--	---	--

	9	Kim "Oncolytic Virotherapy for Cancer with Adenovirus D11520 (Onyx-015): Results of Phase I and II Trials", Expert Opinion Biol. Ther., 1(3): 525-538, 2001. Abstract.
--	---	--

↓	10	Merritt et al. "Clinical Evaluation of Adenoviral-Mediated P53 Gene Transfer: Review of INGN 201 Studies", Semin. Oncol., 28(Suppl. 16): 105-114, 2001. Abstract.
---	----	--

Ami	11	Banerjee "Genasense (Genta Inc)" Current Opinion Investig. Drugs, 2(4):574-580, 2001. Abstract.
-----	----	---

Signature	Anne-Marie Falk	Considered 4/12/05
-----------	-----------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.